3M4 Stock Overview
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Masimo Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$125.70 |
| 52 Week High | US$172.60 |
| 52 Week Low | US$71.70 |
| Beta | 0.98 |
| 1 Month Change | -5.49% |
| 3 Month Change | 7.71% |
| 1 Year Change | -26.75% |
| 3 Year Change | -34.43% |
| 5 Year Change | 5.45% |
| Change since IPO | 738.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3M4 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.3% | 2.1% | 0.5% |
| 1Y | -26.7% | -8.4% | 1.3% |
Return vs Industry: 3M4 underperformed the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: 3M4 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 3M4 volatility | |
|---|---|
| 3M4 Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3M4 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3M4's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 3,800 | Joe Kiani | www.masimo.com |
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions.
Masimo Corporation Fundamentals Summary
| 3M4 fundamental statistics | |
|---|---|
| Market cap | €6.67b |
| Earnings (TTM) | €75.97m |
| Revenue (TTM) | €1.91b |
87.8x
P/E Ratio3.5x
P/S RatioIs 3M4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3M4 income statement (TTM) | |
|---|---|
| Revenue | US$2.05b |
| Cost of Revenue | US$1.04b |
| Gross Profit | US$1.00b |
| Other Expenses | US$922.00m |
| Earnings | US$81.50m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 1.54 |
| Gross Margin | 49.00% |
| Net Profit Margin | 3.98% |
| Debt/Equity Ratio | 66.4% |
How did 3M4 perform over the long term?
See historical performance and comparison